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The mammalian bromodomain protein Brd4 interacts with mitotic chromosomes by binding to acetylated histone H3 and
H4 and is thought to play a role in epigenetic memory. Mitotic cells are susceptible to antimicrotubule drugs. These drugs
activate multiple response pathways and arrest cells at mitosis. We found that Brd4 was rapidly released from chromo-
somes upon treatment with antimicrotubule drugs, including the reversible agent nocodazole. Yet, when nocodazole was
withdrawn, Brd4 was reloaded onto chromosomes, and cells proceeded to complete cell division. However, cells in which
a Brd4 allele was disrupted (Brd4/), and expressing only half of the normal Brd4 levels, were defective in reloading
Brd4 onto chromosomes. Consequently, Brd4/ cells were impaired in their ability to recover from nocodazole-induced
mitotic arrest: a large fraction of/ cells failed to reach anaphase after drug withdrawal, and those that entered anaphase
showed an increased frequency of abnormal chromosomal segregation. The reloading defect observed in Brd4/ cells
coincided with selective hypoacetylation of lysine residues on H3 and H4. The histone deacetylase inhibitor trichostatin
A increased global histone acetylation and perturbed nocodazole-induced Brd4 unloading. Brd4 plays an integral part in
a cellular response to drug-induced mitotic stress by preserving a properly acetylated chromatin status.
INTRODUCTION
Brd4 is a mammalian bromodomain protein that belongs to
the conserved BET family (Dey et al., 2000). The 200-kDa
nuclear protein contains two bromodomains and a long
C-terminal domain. Previous analysis with fluorescence loss
in photobleaching showed that Brd4 dynamically interacts
with acetylated histones H3 and H4 in living interphase cells
(Dey et al., 2003). Extending these observations, we found
that Brd4 and the related Brd2 recognize acetylated histone
codes through the bromodomains (Kanno et al., 2004) and
that acetylated K14 on H3 and K5/12 on H4 are preferred
binding sites of Brd4 (Dey et al., 2003). An additional feature
of Brd4 is that it localizes to chromosomes during mitosis
(Dey et al., 2000). In mitotic cells, Brd4 predominantly re-
sides in the long axes of all chromosomes except centro-
meres where Brd4 is conspicuously absent. Similar to inter-
phase cells, localization of Brd4 to mitotic chromosomes is
attributed at least in part to its binding to acetylated his-
tones. During interphase, Brd4 interacts with other proteins,
including the cyclin T/Cdk9 complex, P-TEFb (Jang et al.,
2005). Brd4 recruits P-TEFb to various promoters in acety-
lated chromatin and participates in RNA polymerase II-
dependent transcription. Based on these properties, Brd4 is
thought to play a role in the inheritance of transcriptional
memory from one generation of cells to the next (Dey et al.,
2003; Loyola and Almouzni, 2004).
Progress has been made in understanding molecular path-
ways that regulate the process of cell division (Mitchison
and Salmon, 2001; Pines and Rieder, 2001). During mitosis,
chromatin undergoes a dramatic change both in conforma-
tion and function. In higher eukaryotic cells, chromatin-
binding proteins, including many bromodomain proteins
(except for Brd4/2) as well as specific and general transcrip-
tion factors, are released from chromatin during mitosis
(Muchardt et al., 1996; Segil et al., 1996). Coinciding with
extensive unloading of factors from chromatin, transcription
becomes globally suspended, rendering the whole genome
inert during mitosis (Muchardt et al., 1996; Segil et al., 1996;
Gottesfeld and Forbes, 1997). Furthermore, core histones are
generally underacetylated, and the activities of histone
acetyltransferases and deaceylases decline during that time
(Kruhlak et al., 2001). The general chromatin hypoacetyla-
tion correlates with the precipitous fall in transcriptional
activities. However, some lysine residues on histones H3
and H4 remain acetylated on mitotic chromosomes, which
may serve as a mark for transcriptional memory (Kruhlak et
al., 2001). Transcription restarts at the end of telophase when
chromatin-binding proteins and transcription factors are re-
loaded onto chromatin (Prasanth et al., 2003). Despite dra-
matic changes in the chromatin status revealed during mi-
tosis, the contribution of chromatin to the progression of
mitosis has remained poorly understood. Recent investiga-
tions, however, begin to shed light on this issue. For exam-
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ple, a short-term histone hyperacetylation brought by a hi-
stone deacetylase inhibitor, trichostatin A (TSA), is shown to
hinder progression from prometaphase to metaphase
(Cimini et al., 2003). The long-term treatment with the inhib-
itor causes chromosomal missegregation, because of alter-
ations in pericentric heterochromatin (Taddei et al., 2001).
A number of structurally diverse agents, such as colchi-
cine, Vinca alkaloids, and paclitaxel target microtubules and
interfere with the formation of mitotic spindles. These drugs
elicit potent antimitotic effects and arrest cells at around
prometaphase (Bhalla, 2003; Jordan and Wilson, 2004). No-
codazole is one such drug whose effects are reversible:
whereas the drug causes extensive depolymerization of mi-
crotubules and complete mitotic arrest, its withdrawal leads
to rapid reformation of mitotic spindles and resumption of
mitosis. For its reversible effect on mitosis, nocodazole has
been extensively used in biochemical and cell biological
studies.
Many microtubule-targeting agents, extracted from plant
and animal products, are thought to have evolved as a
strategy for self-protection. Alternatively, animal cells are
also equipped with mechanisms to respond to antimitotic
effects of these agents. Cells activate checkpoints, such as
mitotic stress checkpoints and spindle assembly checkpoints
(Rudner and Murray, 1996; Scolnick and Halazonetis, 2000;
Nigg, 2001; Cleveland et al., 2003; Rieder and Maiato, 2004),
to halt progression of mitosis. Activation of checkpoints
presumably helps cells to prepare for future recovery from
drug-induced damage (Sorger et al., 1997; Bhalla, 2003). Fur-
thermore, several mitogen-activated protein kinases are ac-
tivated in many cells in response to antimicrotubule drugs,
including extracellular signal-regulated kinases 1/2, p38,
and c-Jun NH2-terminal kinases (JNKs) (Haynes et al., 1992;
Takenaka et al., 1998; Wang et al., 1998). Activation of these
kinases seems to protect the survival of some cells, whereas
promoting apoptosis of other cells (Wang et al., 1998;
Yamamoto et al., 1999).
Here, we show that addition and withdrawal of nocoda-
zole causes a dramatic redistribution of Brd4 from and to
mitotic chromosomes in mouse cells. This drug-induced
Brd4 dynamics was impaired in Brd4/ cells, in which
specific lysine residues in histones H3 and H4 were under-
acetylated relative to those in Brd4/ cells. Our results
indicate that drug-induced Brd4 dynamics is regulated by
the patterns of acetylated histone codes that are recognized
and maintained by Brd4. We show that Brd4 dynamics
critically contributes to the recovery from nocodazole-in-
duced mitotic arrest, facilitating resumption of mitosis after
drug removal. This work supports the view that chromatin
and Brd4 dynamics play an integral part in cellular re-
sponses to drug-induced mitotic stress.
MATERIALS AND METHODS
Cells and Drug Treatment
Murine embryonic stem (ES) cells (EB3) (Niwa et al., 2000) and Brd4/
clones were maintained on gelatin-coated dishes in G-MEM supplemented
with 10% fetal bovine serum, 2 mM glutamine, 0.1 mM nonessential amino
acids, 1 mM pyruvate, 0.1 mM 2-mercaptoethanol, 1000 U/ml leukemia
inhibitory factor (Chemicon International, Temecula, CA), and 5 g/ml blas-
ticidin S. Cells (1.5  105/ml) were treated with 100 ng/ml nocodazole,
colcemid, or paclitaxel (all purchased from Sigma-Aldrich, St. Louis, MO)
dissolved in dimethyl sulfoxide (DMSO) at 37°C for indicated periods of time.
For control experiments, cells were treated with equivalent concentration of
DMSO. In some experiments, cells were treated with TSA (50 ng/ml) in the
presence or absence of nocodazole (100 ng/ml) for 6 h.
Targeted Disruption of the Brd4 Gene
BAC clones containing the murine Brd4 locus were isolated by the Do-It-
Yourself PCR screening kits (Mouse ES BAC, Release I) (Incyte, Wilmington,
DE). A targeting vector was constructed by placing the NcoI (7.5-kb) and
HindIII-XhoI (3.4-kb) fragments upstream and downstream of the SA-IRES-
linked selection cassette containing the puromycin resistant gene, respectively
(Figure S1A) (Mountford et al., 1994; Niwa et al., 2000). Two  107 cells were
electroporated with 100 g of the linearized targeting vector at 800 V and 3 F
and selected in the presence of 0.3 g/ml puromycin. Clones with a disrupted
Brd4 gene were identified by Southern blot analysis using probes external to
the recombination construct (Figure S1B).
Transfection and Live Cell Imaging
Two  104 cells were seeded on a Lab-Tek chambered cover-glass (Nalge
Nunc International, Naperville, IL) and after overnight incubation, cells were
transfected with 0.2 g of an expression vector for green fluorescent protein
(GFP)-labeled wild-type Brd4 (Maruyama et al., 2002) using FuGENE 6 (Roche
Diagnostics, Indianapolis, IN) according to the manufacturer’s instructions
and incubated for 12 h before treatment. Cells were treated with indicated
drugs for 4 h in phenol red-free media. For drug withdrawal experiments,
mitotic cells were harvested after 8 h of nocodazole treatment by mitotic
shake-off and reincubated in a Lab-Tek chamber for indicated times. Hoechst
33342 (1 g/ml) was added to media immediately before microscopic obser-
vations. Cells were viewed with a Leica TCS-SP2 confocal laser scanning unit
equipped with UV, Ar, and Kr laser beams and attached to a Leica DMIRE2
inverted microscope using a 63 oil immersion objective. Images were ac-
quired by using the Leica confocal software version 2.5.
Immunofluorescence Staining
Nocodazole-treated cells were cytospun and fixed with 4% paraformaldehyde
in phosphate-buffered saline (PBS) for 1 h at room temperature and perme-
abilized with methanol for 10 min. Antibodies against -tubulin was pur-
chased from Sigma-Aldrich. Rabbit antibodies to Brd4, indirect immunoflu-
orescent staining and counterstaining with Hoechst 33342 were described
previously (Dey et al., 2000). Immunostaining of untreated cells (control) was
performed with cells cultured on poly-l-lysine-coated coverslips using the
same procedures as described above. Staining with the human ANA-centro-
mere autoantibody (CREST) (Cortex Biochem, San Leandro, CA) and Alexa
Flour 568 goat anti-human IgG (Molecular Probes, Eugene, OR) was per-
formed as described previously (Zhang et al., 2004). Stained cells were viewed
as described above.
Flow Cytometry Analysis and Clonogenic Survival Assay
Cells (1.5  105/ml) treated with nocodazole for 8 h at 100 ng/ml were
collected by mitotic shake-off and reincubated for indicated times. For detect-
ing apoptosis, cells were stained with Annexin V-fluorescein isothiocyanate
(BD Biosciences PharMingen, San Diego, CA) according to the manufacturer’s
instructions. Stained cells were analyzed on FACSCalibur with the CellQuest
software (BD Biosciences, San Jose, CA). For assessing DNA contents, cells
were stained with propidium iodide (25 g/ml) and analyzed as described
above. For clonogenic survival assay, mitotic cells harvested after 8 h of
nocodazole treatment were plated in a well of six-well plates (200 cells/well)
and incubated in fresh media for 7 d. Colonies were fixed with 4% parafor-
maldehyde in phosphate-buffered saline (PBS) and stained with crystal violet.
Cell masses 0.5 mm in diameter were counted as colonies.
Cdk1 Kinase Assays
Whole cell lysates were prepared from 5  105 nocodazole-treated/released
cells by incubating in 100 l of NP-40 buffer containing 50 mM Tris-HCl, pH
8.0, 150 mM NaCl, 1.0% NP-40, the protease inhibitor cocktail (Roche Diag-
nostics), and phsophatase inhibitors (50 mM sodium fluoride, 1 mM sodium
orthovanadate, and 0.1 mM ammonium molybdate) for 20 min on ice. After
removing debris by centrifugation, 30 g of clear lysates was immunopre-
cipitated with 4 l of anti-cyclin B1 antibody (Santa Cruz Biotechnology,
Santa Cruz, CA). Precipitates were incubated with 10 Ci of [-32P]ATP (MP
Biomedicals, Irvine, CA) in the presence of 20 g of histone H1 (Upstate
Biotechnology, Lake Placid, NY) in a total reaction volume of 50 l at 30°C for
10 min. Reaction mixtures were transferred to P81 phosphocellulose paper
and counted in a scintillation counter.
Histone Purification and Immunoblot Analysis
Histones were isolated according to the method described previously (Braun-
stein et al., 1993) with modifications. One million cells were suspended in lysis
buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl2. 10 mM KCl, 0.5 mM dithio-
threitol, and 0.2 M sulfuric acid), incubated on ice for 30 min, and centrifuged.
The supernatants were dialyzed against 0.1 M acetic acid twice and water
three times. Immunoblot analysis was performed with 15 g of extracts and
antibodies for unacetylated histones H3 and H4 and those acetylated at
indicated lysine residues (all from Upstate Biotechnology, except for H4AcK5,
which was from Serotec, Oxford, United Kingdom). Reactions were visual-
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ized by enhanced chemiluminescence. To quantify immunoblot data, the
band intensity was determined by the NIH Image (version 1.63) software.
RESULTS
Nocodazole Reversibly Releases Brd4 from Mitotic
Chromosomes
During mitosis, Brd4 localizes to noncentromeric axes of
chromosomes by binding mostly to acetylated histones H3
and H4 (Dey et al., 2000, 2003). We found that antimicrotu-
bule drugs trigger dissociation of Brd4 from chromosomes
in various cultured cells. Shown in Figure 1A is immuno-
staining of endogenous Brd4 in murine EB3 ES cells treated
with nocodazole, colcemid, and paclitaxel. The former two
drugs inhibit tubulin polymerization, whereas the latter pro-
motes its polymerization (Jordan and Wilson, 2004). When
treated with these drugs for 4 h at 100 ng/ml, Brd4 staining
was detected entirely outside of condensing chromosomes
stained for DNA: at this dose of the drugs, all mitotic cells in
the fields showed complete dissociation of Brd4 from chro-
mosomes. In contrast, Brd4 staining was restricted to chro-
mosomes in mitotic cells treated with vehicle (DMSO) alone,
as expected (see control in Figure 1A where Brd4 staining
overlaps with DNA staining on a mitotic plate). Immuno-
staining of -tubulin in Figure 1A verified that these drugs
inhibited formation of proper mitotic spindles. To exclude
the possibility that the observed dissociation of Brd4 from
chromosomes is because of an artifact of fixation or other
procedures used in this work, we visualized the movement
of an exogenous Brd4 in live cells by transfecting a Brd4
vector fused to the GFP in ES cells. We have previously
shown that GFP-Brd4 interacts with acetylated chromatin
and behaves in a manner indistinguishable from that of the
endogenous Brd4 (Dey et al., 2003). As shown in Figure 1B,
GFP-Brd4 was again completely dispersed from mitotic
chromosomes after drug treatment. These results indicate
that Brd4 is unloaded from chromosomes in response to
antimicrotubule agents.
Nocodazole is a reversible agent, and upon its removal,
spindles reform and cells resume mitosis (Rieder and Ma-
iato, 2004). We found that Brd4 reassociated with mitotic
chromosomes after nocodazole was removed from the cul-
ture. In Figure 1C, cells that had been treated with nocoda-
zole for 8 h were washed, mitotic cells were then incubated
in fresh media for varying times up to 45 min, and the
localization of Brd4 was examined by immunostaining. Dur-
ing the initial 15 min after nocodazole withdrawal, Brd4
remained dissociated from chromosomes in most cells. Soon
afterward, however, Brd4 began to relocalize to chromo-
somes. At 30 min after drug withdrawal, when cells ap-
proached metaphase, Brd4 was seen reloaded onto chromo-
somes in the majority of cells. In these cells, reformation of
mitotic spindles was evident (Figure 1C, see immunostain-
ing of -tubulin). Relocalization of Brd4 onto chromosomes
was further increased in anaphase/telophase cells at 45
min, when 75% of cells showed Brd4 on segregating chro-
mosomes. In untreated control cells, Brd4 remained on mi-
totic chromosomes during the entire period of mitosis, in-
cluding anaphase/telophase as noted previously (Figure 1C;
Dey et al., 2000). Reassociation of GFP-Brd4 with mitotic
chromosomes was also observed in live cells after nocoda-
Figure 1. Redistribution of Brd4 after addi-
tion and removal of antimicrotubule drugs.
(A) Murine ES cells (1.5  105/ml) were
treated with indicated drugs (100 ng/ml) for
4 h. Cell were cytospun, fixed, and immuno-
stained to detect Brd4 (green) and -tubulin
(red), and counterstained by Hoechst 33342
for DNA (blue). (B) Cells were transfected
with GFP-Brd4 vector for 12 h and treated
with indicated agents as described in A. GFP
signals (green) were viewed along with
Hoechst 33342 signal (blue) in live cells. (C)
Cells that had been treated with nocodazole
(100 ng/ml) for 8 h were washed and incu-
bated in fresh media for indicated times and
immunostained as described above. (D) GFP-
Brd4-expressing ES cells were treated as de-
scribed in C and viewed as described in B.
Bar, 5 m.
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zole removal (Figure 1D). Similar dissociation from and
reassociation with mitotic chromosomes was observed for
Brd4 in P19 and other cell types upon nocodazole addition
and withdrawal (Nishiyama, Dey, Ito, and Ozato, unpub-
lished data). Thus, Brd4 is unloaded from chromosomes
after nocodazole treatment when mitosis is arrested and
reloaded onto chromosomes upon drug withdrawal when
mitosis restarts.
Brd4 Reloading Is Compromised in Brd4 Heterozygous
(/) Cells
The dramatic redistribution of Brd4 after nocodazole addi-
tion and withdrawal suggested that Brd4 has a role in a
cellular response to antimicrotubule drugs. We sought a
genetic approach to address the significance of Brd4 dynam-
ics in a mitotic stress caused by antimicrotubule drugs. With
the aim of studying Brd4 null cells, we first constructed ES
cells in which a Brd4 allele was disrupted. Our targeting
strategy (Figure S1) yielded many Brd4/ clones. How-
ever, our attempts to disrupt the other Brd4 allele were
unsuccessful, suggesting that Brd4 is essential for cell
growth. In accord with our results, Brd4/ mice con-
structed by a gene trap strategy, are reported to be early
embryonic lethal (Houzelstein et al., 2002). To investigate a
possible haploinsufficiency for Brd4, three Brd4/ clones
(C12, C16, and C27) were established. Brd4 protein levels in
these clones and other Brd4/ cells were consistently
about one-half that of Brd4/ cells (Figure 2A). Brd4/
cells from all three clones grew at a rate comparable with
that of Brd4/ cells with no apparent growth disadvan-
tage under normal culture conditions (Figure S2A). In addi-
tion, Brd4/ clones and Brd4/ cells were equally ca-
pable of arresting mitosis after nocodazole addition, because
they showed essentially the same mitotic indices observed at
2, 4, 6, and 8 h after drug addition (Figure S2B). This indi-
cates that Brd4/ cells did not prematurely enter mitosis
upon nocodazole addition and mitotic checkpoints func-
tioned in both cells (Scolnick and Halazonetis, 2000;
Mikhailov and Rieder, 2002; Peters, 2002; Cleveland et al.,
2003). We noted, however, that mitotic indices were slightly
reduced when tested at 12 h for both / and / cells,
indicating that a certain fraction of cells escape from mitotic
arrest after extended nocodazole treatment (our unpub-
lished data). The localization of Brd4 in / cells was
identical to that in Brd4/ cells in the absence of nocoda-
zole: it was restricted to mitotic chromosomes. Likewise,
Brd4 was released from chromosomes both in / and
/ cells after drug addition, indicating that Brd4 unload-
ing occurred normally in / cells after nocodazole treat-
ment (our unpublished data). However, Brd4/ cells
were clearly defective in Brd4 reloading after nocodazole
withdrawal. Brd4 remained in the extrachromosomal space
at 30 min after nocodazole removal when the majority of
/ cells showed Brd4 reloading. Even at anaphase/telo-
phase when chromosomes were segregating toward oppo-
site poles, Brd4 resided in the space outside of chromosomes
in many / cells (see an example in Figure 2B). In Figure
2C, we quantified the number of anaphase/telophase cells in
which Brd4 was successfully reloaded onto chromosomes
after nocodazole withdrawal. More than 70% of Brd4/
cells showed complete Brd4 reloading at 40 min. In contrast,
only 20–30% of / cells had Brd4 on segregating chromo-
somes in all three Brd4/ clones. There was a small pro-
portion of Brd4/ cells in which Brd4 reloading seemed
incomplete. This may be because of incomplete elimination
of the drug from the cells and/or altered Brd4 expression
levels. To exclude the possibility that the defect seen in/
clones was because of transfection of targeting vector, we
examined several ES clones obtained after transfection of a
control vector. Brd4 in these clones was reloaded onto chro-
mosomes after nocodazole removal in a manner identical to
that of parental cells (our unpublished data). Once cells
completed mitosis and entered G1 phase, Brd4 associated
with chromatin in Brd4/ cells in a manner very similar
to that in Brd4/ cells. This was evident by the identical
salt solubility of Brd4 in / and / cells in G1 cells
generated after nocodazole withdrawal (Figure S3). These
results indicate that Brd4/ cells are haploinsufficient for
Brd4 reloading, suggesting the importance of Brd4 expres-
sion levels.
Figure 2. Defective Brd4 reloading in Brd4/ cells. (A) Reduced
Brd4 levels in Brd4/ clones. Immunoblot analysis was per-
formed with the whole cell lysates (30 g) from parental ES cells
(WT) and three representative Brd4/ clones (C12, C16, and C27)
for Brd4 and -tubulin as a loading control. (B) Brd4/ and /
cells were treated with nocodazole for 8 h; mitotic cells were incu-
bated in fresh media for 40 min and immunostained for Brd4
localization. Left, an example of a Brd4/ cell in which Brd4 was
fully reloaded on the segregating chromosomes. -Tubulin was
stained to visualize mitotic spindles. Right, an example of a
Brd4/ cell in which Brd4 remained outside of the segregating
chromosomes. Bar, 5 m. (C) Brd4 reloading was monitored by
immunostaining of parental Brd4/ and three / clones that
had been treated with nocodazole and released in fresh media for 40
min as described above. The black columns represent the percent-
age of cells in which Brd4 was reloaded on chromosomes, and the
white columns represent those in which Brd4 was not reloaded on
chromosomes. A representative of three independent tests is shown.
More than 200 cells with segregating chromosomes (anaphase/
telophase cells) were examined in each experiment.
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Brd4/ Cells Are Haploinsufficient for the Ability to
Recover from Nocodazole-induced Mitotic Arrest
If nocodazole-triggered Brd4 dynamics is a part of cellular
responses to mitotic stress, then the capacity to reload Brd4
onto chromosomes may signify the cell’s ability to recover
from drug-induced mitotic arrest. To test this possibility, we
next examined progression of / and / cells to an-
aphase after nocodazole withdrawal. Cells that had been
treated with nocodazole for 8 h were washed, mitotic cells
were allowed to proceed in fresh media for varying times up
to 60 min. Cells in anaphase/telophase carrying segregating
chromosomes were detected by DNA staining. As shown in
Figure 3A, there were few anaphase/telophase cells at 20
min, but their number was sharply increased at 40 min in
/ cells, where 40% of cells were in anaphase/telo-
phase, in agreement with the timing of mitosis seen in
Figure 1C. By 60 min most of / cells completed mitosis
and there were few remaining cells with segregating chro-
mosomes. In contrast, / cells from all three clones
showed much fewer anaphase/telophase cells at the peak
time of 40 min: only 15% of / cells carried segregating
chromosomes at this stage. There were few anaphase/telo-
phase cells before and after the peak time. These results
indicate that a large fraction of Brd4/ cells failed to
resume mitosis and did not reach anaphase. That the per-
centage of anaphase/telophase cells in / clones was as
low as / cells at 20 min before the peak time indicates
that / cells did not prematurely enter anaphase. Simi-
larly, the results that the percentage of anaphase/telophase
cells fell at 60 min in / clones in the same manner as in
/ cells indicate that the reduction in anaphase/telophase
cells in / clones was not because of a delayed progres-
sion to anaphase.
Increased Chromosomal Missegregation in Brd4/ Cells
Although markedly reduced, a fraction of Brd4/ cells
reached anaphase after nocodazole removal. In many of
these cells, segregating chromosomes did not carry Brd4,
because it remained unloaded. It was of interest to assess
whether progression to anaphase/telophase occurred nor-
mally in these Brd4/ cells. To this end, we examined
sister chromatid separation and chromosomal segregation in
/ and / cells after nocodazole withdrawal. Cells that
had been treated with nocodazole were allowed to proceed
for 40 min in fresh media to reach anaphase/telophase, and
the segregating chromosomes were morphologically in-
spected after staining of DNA and Brd4. We observed a
significant increase in chromosomal missegregation in /
cells, mostly the form of misdistributed chromosomes with a
morphology resembling lagging chromosomes or chromo-
some fragments. In theses cells, some chromosomes/frag-
ments seemed left behind near the mitotic plate, whereas
other chromosomes moved toward spindle poles (Figure
3B). Chromosomal bridges were another type of abnormal-
ity observed after nocodazole treatment, in which sister
chromatid arms remained incompletely separated (Figure
Figure 3. Brd4/ cells are haploinsufficient in mi-
totic progression after nocodazole removal. (A) Im-
paired anaphase progression in Brd4/ cells after
nocodazole withdrawal. Brd4/ and / cells
were treated with nocodazole (100 ng/ml) for 8 h.
Mitotic cells were then allowed to proceed in fresh
media for indicated times (minutes) and stained for
Brd4 and DNA. Cells carrying segregating chromo-
somes were scored as those that progressed to an-
aphase/telophase. A representative of three indepen-
dent tests is shown. At least 250 cells were examined
in each experiment. (B) Abnormal chromosomal seg-
regation in Brd4/ cells. Segregating chromo-
somes were detected by visualizing stained DNA. An
example of chromosomal bridge (Bridge) and misdis-
tributed chromosome (Lagging/Fragment) is shown.
Note that Brd4 remained unloaded in both cases. Bar,
5 m. (C) The percentage of dividing cells carrying
abnormal chromosomal segregation is shown. A rep-
resentative of three independent tests is shown. More
than 200 anaphase/telophase cells were inspected in
each experiment. (D) The percentage of dividing
Brd4 / cells showing CREST signals on misdis-
tributed chromosomes is shown. More than 200 an-
aphase/telophase cells were inspected. (E) Brd4/
cells incubated for 40 min after release from nocoda-
zole treatment (100 ng/ml; 8 h) were fixed and im-
munostained with antibody for CREST (green) and
-tubulin (red) and counterstained for DNA (blue).
CREST staining of a lagging chromosome is marked
by arrow. Bar, 5 m.
A. Nishiyama et al.
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3B). Figure 3C compares the frequency of cells with abnor-
mal chromosomal segregation in Brd4/ and / cells.
In line with the reports that nocodazole treatment increases
the frequency of chromosomal missegregation in human
fibroblasts and PtK1 cells (Cimini et al., 1999, 2001), chromo-
somal missegragation was seen in 17% of Brd4/ cells.
However, the frequency of chromosomal missegregation
was much higher in Brd4/ cells:50% of Brd4/ cells
carried abnormal chromosomes in all three clones. Kineto-
chore staining with CREST antibody revealed that most of
misdistributed chromosomes in Brd4/ cells were lag-
ging chromosomes rather than chromosomal fragments
(Figure 3E). Eighty percent of misdistributed chromosomes
showed the kinetochore staining (Figure 3D). These results
indicate that Brd4/ cells are more prone to have chro-
mosomal missegregation than Brd4/ cells after nocoda-
zole treatment.
Nocodazole Treatment Increases Apoptosis as Well as
Tetraploidy in Brd4/ Cells, Leading to Reduced
Proliferative Capacity
Given that Brd4/ cells are defective in entering an-
aphase, it was of interest to assess whether some / cells
succumb to programmed cells death after nocodazole with-
drawal. Figure 4A examines the percentage of apoptotic cells
after nocodazole removal by Annexin V staining. The per-
centage of Annexin V-positive apoptotic cells was 30% in
Brd4/ cells, whereas that in Brd4/ cells was 13%.
Annexin V-positive cells were 10% at the time of release
for both Brd4/ and / cells. These data indicate that
Brd4/ cells are susceptible to apoptotic cell death to a
greater extent than Brd4/ cells after nocodazole treat-
ment. It is possible that in addition to increased apoptosis,
some Brd4/ cells escaped from mitosis without complet-
ing cell division. If so, Brd4/ daughter cells generated
after nocodazole withdrawal may have tetraploid (or near
teraploid) genomes. In Figure 4B, flow cytometry was car-
ried out to assess DNA content in / and / cells
harvested after nocodazole release. The frequency of cells
carrying 4N DNA was substantially higher in Brd4/
cells than/ cells (55 vs. 35%). The above-mentioned data
show that Brd4/ cells are more susceptible to nocoda-
zole-inflicted damage during mitosis than / cells and
raise the possibility that nocodazole treatment/withdrawal
has a lasting effect on Brd4/ cell growth. We thus per-
formed clonogenic assays where cells were first treated with
varying concentrations of nocodazole for 8 h, and mitotic
cells were allowed to grow as colonies for subsequent 7 d in
the absence of the drug. Of 200 cells seeded, 95–175 colo-
nies arose from untreated cells from both Brd4/ and
/ cells with some variability in experiments, indicating
that the colony-forming ability was comparable in untreated
Brd4/ and / cells. However, the colony-forming
ability was markedly reduced in Brd4/ cells that had
been treated with nocodazole. Quantification of the number
of colonies that arose after nocodazole treatment is pre-
sented in Figure 4C. In Brd4/ cells, nocodazole treat-
ment reduced the number of colonies at most by 20%. In
contrast, in all three Brd4/ clones, nocodazole treatment
at all does tested led to a more severe reduction in colony
numbers. At the highest dose of the drug (500 ng/ml), the
number of colonies fell to 50% of that of / cells. These
data indicate that the failure to reload Brd4 onto chromo-
somes after nocodazole removal has multiple functional
consequences and results in growth inhibition in Brd4/
cells.
Cyclin B1/Cdk1 Is Similarly Inactivated in Brd4/ and
/ Cells
Anaphase entry is triggered by the activation of the an-
aphase-promoting complex (APC), marked first by the inac-
tivation of cyclin B1/Cdk1 (Clute and Pines, 1999; Nigg,
2001; Peters, 2002). Impaired anaphase entry observed with
Brd4/ cells after nocodazole removal suggested that
these cells may be defective in activating the APC. To test
this possibility, we examined Cdk1 kinase activity in
Brd4/ and / cells. Cells were treated with nocoda-
zole and released into fresh media for varying times. As
presented in Figure 5A, Cdk1 kinase activity was the highest
at the time of nocodazole removal (time 0). The kinase
activity declined sharply thereafter and fell to background
levels by 60 min both in Brd4/ and / cells. In accor-
dance, cyclin B1 protein levels detected by immunoblot were
the highest at time 0 and precipitously declined afterward
both in Brd4/ and / cells at similar extents (Figure
5B). We also tested phosphorylation of Cdc27 and Cdk1 and
found that it was also comparable in Brd4/ and /
cells (our unpublished data). These results indicate that the
APC was activated in Brd4/ cells and that the processes
that accompanied APC activation took place in Brd4/
cells. Thus, the failure of Brd4/ cells to enter anaphase
Figure 4. Impaired recovery from nocodazole-induced mitotic ar-
rest in Brd4/ cells. (A) The percentage of apoptotic cells after
nocodazole removal. Cells released from nocodazole treatment (100
ng/ml for 8 h) were stained for Annexin V and analyzed by flow
cytometry. The values represent the average of three experiments.
(B) DNA contents after nocodazole withdrawal. Cells released from
nocodazole as mentioned above were stained with propidium io-
dide and analyzed by flow cytometry. (C) Clonogenic survival after
nocodazole treatment. Brd4/ and / cells were treated with
indicated concentrations of nocodazole for 8 h. Two hundred mi-
totic cells were replated in a well and allowed to grow in fresh
media, and colonies were counted 7 d later. Untreated Brd4/
and / cells yielded comparable numbers of colonies. Values
represent the average of three independent assays.
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was apparently not because of the global lack of APC acti-
vation. However, it is still possible that Brd4/ cells are
impaired in some pathways downstream of APC activation,
leading to the anaphase block observed after nocodazole
withdrawal.
Underacetylation of the Brd4-binding Histone Residues in
Brd4/ Cells
The interaction of Brd4 with mitotic chromosomes depends
largely on acetylated core histones, as is the case for binding
of Brd4 to chromatin during interphase (Dey et al., 2003). We
next sought to assess the status of chromatin acetylation in
Brd4 / cells. If altered in / cells, we wished to
address whether the alteration could account for the defects
in Brd4/ cells observed by nocodazole treatment. This
question was of importance because it has not been clear
whether Brd4 has a role in preserving chromatin acetylation,
whereas it is clear that Brd4 binds to acetylated chromatin
(Dey et al., 2003). Histones prepared from randomly growing
cells (control), cells arrested at mitosis by nocodazole treat-
ment, and cells released from nocodazole for varying times
up to 60 min were tested for acetylation of H3 and H4 by
immunoblot analysis. The use of specific antibodies allowed
us to assess acetylation of individual lysine residues on the
histones (Figure 6A). Antibodies for unacetylated H3 and
H4 served as loading controls. As expected of histone hy-
poacetylation during mitosis, levels of acetylated H3 and H4
were lower in mitotically arrested and released cells than in
randomly growing cells (0–60 min in Figure 6A) in both
Brd4/ and / cells. All lysine residues tested here, K9
and K14 of H3 and K5, 8, 12, and K16 of H4 showed lower
acetylation in mitotic (nocodazole treated/released) cells.
Significantly, the levels of acetylated K14 on H3 and acety-
lated K12 on H4 were consistently lower in Brd4/ cells
than in / cells in all stages of the culture examined
(Figure 6A). This was confirmed by densitometry analysis of
immunoblots in Figure 6B. The band intensity of these acety-
lated residues in Brd4/ cells was 50% of that /
cells. However, the level of acetylation in other residues was
not altered in Brd4/ cells. These results are interesting,
because K14 of H3 and K12 of H4 are thought to be binding
sites of Brd4 (Dey et al., 2003). We also noted that under-
acetylation of K12 of H4 in Brd4/ cells relative to /
cells seemed more pronounced in nocodazole treated/re-
leased cells than in randomly growing cells. In contrast, K14
of H3 seemed underacetylated in / cells in all stages of
cultures relative to / cells. The reduction of acetyl H3
K14 and acetyl H4 K12 was observed with other/ clones
(our unpublished data). These results indicate that Brd4 has
a role in the maintenance of acetylated K14 in H3 and K12 in
Figure 5. Comparable Cdk1 kinase activity and cyclin B degrada-
tion in Brd4/ and / cells. (A) Cdk1 activity was tested with
histone H1 as a substrate using precipitates of lysates (30 g) from
Brd4/ and / cells that had been treated with nocodazole at
100 ng/ml for 8 h and incubated in fresh media for indicated times
(minutes). Values represent the average of three samples. (B) Ly-
sates in A were subjected to immunoblot analysis to detect cyclin B1
and Cdk1 expression. -Tubulin was immunoblotted as a control.
Figure 6. Histone hypoacetylation in Brd4/ cells. (A) Acetyla-
tion of histones H3 and H4 was tested by immunoblot analysis with
indicated antibodies using histones extracted from untreated (con-
trol) Brd4/ and/ cells and treated with nocodazole followed
by incubation in fresh media for indicated times (minutes). (B)
Immunoblot data for acetylated K14 on H3 and acetylated K12 on
H4 shown in A were quantified by densitometry analysis. The band
intensity of histones acetylated at K14 and K12 was normalized with
the intensity of unacetylated H3 and H4 on each time point and
expressed as the percentage of intensity in which the value for
untreated Brd4/ cells (control) was taken as 100%.
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H4 in these cells. Because Brd4 itself does not catalyze his-
tone acetylation/deacetylation, the maintenance of acety-
lated chromatin by Brd4 is likely to involve a nonenzymatic
mechanism.
Enhanced Histone Acetylation Inhibits Nocodazole-
induced Brd4 Unloading
The above-mentioned data suggested the possibility that
histone acetylation is a key mechanism to regulate nocoda-
zole induced redistribution of Brd4. To assess how an alter-
ation of histone acetylation affects Brd4 dynamics, we next
tested the effect of a histone deacetylase inhibitor, TSA (Yo-
shida et al., 1995), on nocodazole-induced Brd4 unloading.
Brd4/ and / cells were treated with or without no-
codazole for 6 h in the presence or absence of TSA (50
ng/ml). Figure 7A shows changes in the levels of H3 and H4
acetylation detected by immunoblot analysis. In the absence
of TSA, both H3 and H4 were hypoacetylated in nocodazole-
treated, mitotically arrested cells relative to untreated cells,
as observed in Figure 6. K14 on H3 and K12 of H4 in
Brd4/ cells were less acetylated relative to those in
Brd4/ cells, again noted in Figure 6. Importantly, TSA
treatment greatly increased acetylation of H3 and H4 in both
cells irrespective of nocodazole treatment: the levels of acet-
ylation were comparable in Brd4/ and / cells, in-
cluding those for K14 on H3 and K12 on H4. Furthermore,
the increase seemed broad as seen in increases in diacety-
lated H3 and tetra-acetylated H4. In nocodazole-treated
samples, Ser10 in H3 was phosphorylated at equivalent
levels in Brd4/ and/ cells in the presence or absence
of TSA treatment, indicating that TSA did not inhibit no-
codazole-induced mitotic arrest.
We next tested whether TSA treatment altered nocoda-
zole-induced Brd4 unloading. Brd4/ and / cells
were treated with TSA plus nocodazole under the same
conditions as described above. Results of immunostaining
are shown in Figure 7B. Brd4 was not released from chro-
mosomes when cells were treated with TSA and nocodazole
both in Brd4/ and / cells. In virtually all cells exam-
ined, Brd4 remained localized on mitotic chromosomes.
When cells were treated with nocodazole alone, Brd4 was
released from chromosomes tested in parallel as controls
(Figure 7B). TSA treatment did not affect nocodazole-in-
duced mitotic arrest as judged by DNA staining and cellular
morphology. Similarly, TSA did not affect nocodazole-in-
duced microtubule depolymerization, because -tubulin
was uniformly distributed in the presence and absence of
TSA. These results indicate that histone acetylation has a
major effect on nocodazole-induced Brd4 redistribution, and
abnormal augmentation of histone acetylation inhibits no-
codazole-induced Brd4 unloading. It is worth noting here
that although TSA increased chromatin acetylation in a
global manner, it did not restore the ability to enter an-
aphase, rather TSA treatment reduced the number of cells
entering anaphase both in Brd4/ cells and / cells
(our unpublished data). This is consistent with the previous
reports showing that TSA treatment inhibits mitotic progres-
sion (Cimini et al., 2003; Mikhailov et al., 2004). These results
indicate that Brd4 unloading is an event critical for recovery
from nocodazole-induced mitotic arrest.
DISCUSSION
Here, we describe a striking dynamics that Brd4 displays in
response to an antimitotic drug, nocodazole. Brd4 was re-
leased from prometaphase chromosomes after nocodazole
addition. Brd4 was reloaded onto metaphase chromosomes
within 30 min after nocodazole withdrawal and continued
to associate with chromosomes for the remaining course of
mitosis. Brd4/ cells exhibited clear haploinsufficiency in
reloading and manifested multiple deficiencies in the sub-
sequent mitotic progression, illustrating that the ability to
reload Brd4 onto chromosomes correlates with the capacity
to recover from nocodazole-induced mitotic arrest and to
complete cell division. We show that the observed Brd4
haploinsufficiency is linked to reduced acetylation of core
histones in Brd4/ cells. Together, our results indicate
that acetylated histone codes on mitotic chromosomes influ-
ences an antimitotic stress response caused by nocodazole in
cultured cells.
Unloading and Reloading of Brd4
Brd4 was released from chromosomes after addition of no-
codazole and other microtubule-disrupting agents. Brd4 was
released by these drugs not only in ES cells tested here but
also in many other cell types, indicating that unloading of
Brd4 is a widespread response of mammalian cells to anti-
mitotic agents. Our evidence obtained from P19 cells indi-
cates that Brd4 unloading is in part mediated by its C-
terminal domain and is dependent on activation of a kinase
Figure 7. TSA inhibits nocodazole-induced Brd4 unloading. (A)
Hyperacetylation of histones by TSA. Brd4/ and/ cells were
treated with nocodazole (100 ng/ml) or TSA (50 ng/ml) alone or
both for 6 h, and histones H3 and H4 were analyzed for acetylation
or phosphorylation of indicated residues. (B) Brd4/ and /
cells were treated with nocodazole and TSA for 6 h as in A, and
localization of endogenous Brd4 was visualized by immunostain-
ing. Bar, 5 m.
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in the JNK pathway triggered by these drugs (Nishiyama,
Dey, Ito, and Ozato, unpublished data).
Although the release of Brd4 from chromosomes upon
addition of antimicrotubule drugs is a prominent event, it is
not clear whether other chromosomal proteins are also re-
leased from chromosomes in response to these agents. Nev-
ertheless, it is important to note here that antimicrotubule
drugs have been widely used to identify proteins associated
with mitotic chromosomes (Gasser and Laemmli, 1987; Sai-
toh et al., 1994; Uchiyama et al., 2005). These studies identi-
fied a number of nonhistone proteins, such as topoisomerase
I and II, as constitutive chromosomal proteins. However,
these studies would have excluded Brd4 and other proteins
that might have been released from chromosomes after drug
treatment from the list of “chromosomal proteins,” because
they used antimicrotubule drugs to prepare chromosomes.
Our results may cast a cautionary note on the total reliance
on these drugs for studying proteins associated with mitotic
chromosomes.
Unloading of Brd4 was a temporary response that could
be reversed after nocodazole removal: shortly after drug
withdrawal, the bulk of Brd4 moved back to chromosomes.
However, Brd4/ cells were deficient in this process,
because chromosomes remained without Brd4 in these cells.
The failure to reload Brd4 onto chromosomes had a func-
tional consequence, as observed by impaired entry into an-
aphase/telophase and an increased frequency of chromo-
somal missegregation. Some Brd4/ cells apparently
exited mitosis without cell division as evidenced by in-
creased 4N cells, which may be consistent with comparable
decrease in Cdk1 kinase activity in / and / cells.
Furthermore, Brd4/ cells were impaired in the colony
forming ability after nocodazole treatment, indicating that
postnocodazole proliferation is more compromised in
Brd4/ cells than in / cells. These data indicate that
Brd4 reloading and associated events are an important part
of cellular responses to drug-induced mitotic arrest. Paral-
leling these results, we found that defective Brd4 unloading
is also detrimental to the recovery from drug-induced mi-
totic arrest (Nishiyama, Dey, Ito, and Ozato, unpublished
data). Together, our work supports a view that Brd4 dynam-
ics represents a cellular mechanism by which to minimize
deleterious effects brought by theses drugs.
Mitotic deficiencies noted in nocodazole-treated
Brd4/ cells is not likely to be directly attributable to a
defect in the classical mitotic stress checkpoint or spindle
assembly checkpoints (Rudner and Murray, 1996; Scolnick
and Halazonetis, 2000; Cleveland et al., 2003; Rieder and
Maiato, 2004), because 1) nocodazole arrested Brd4/ and
/ cells similarly at prometaphase, both in terms of kinet-
ics of arrest and dose of the drug; and 2) the timing of
anaphase entry after nocodazole removal was the same in
/ and/ cells. In line with this, the APC was activated
after nocodazole removal in Brd4/ and / cells in a
similar manner, as supported by the comparable fall of Cdk1
kinase activity in / and / cells after drug removal.
However, it is possible that a pathway downstream from the
APC activation may be compromised in / cells, contrib-
uting to the observed defects.
Brd4 Dynamics, the Histone Codes, and Mitotic Stress
Responses
Detailed analysis of acetylated lysine residues in the core
histones showed that Brd4/ cells were hypoacetylated
specifically at K14 of H3 and K12 of H4 in untreated as well
as nocodazole-arrested and released cells. This indicates that
Brd4 expression levels have a direct consequence on the
pattern of histone acetylation. We previously observed that
Brd4 binds to the acetylated K14 of H3 and acetylated K5/
K12 of H4 but not other K residues (Dey et al., 2003). The
present results indicate that Brd4 has an important role in
preserving the acetylation of its binding site. These data
provide the first evidence that Brd4 contributes to the main-
tenance of acetylated histone codes. Thus, inefficient Brd4
reloading observed with Brd4/ cells may be accounted
for by the insufficient acetylation of Brd4 target residues.
TSA markedly increased histone acetylation in Brd4/
and / cells, both during interphase and mitosis, and
abolished histone hypoacetylation known for the mitotic
stage. TSA also inhibited nocodazole-induced Brd4 unload-
ing. This and the fact that Brd4 reloading was compromised
in / cells where histones were hypoacetylated at specific
residues indicate that Brd4 dynamics is dependent on
proper histone acetylation patterns. This suggests that the
recovery from mitotic arrest also depends on proper histone
acetylation patterns. Supporting the critical role of appropri-
ately acetylated histones in mitosis, a short-term TSA treat-
ment is shown to delay the prometaphase/metaphase pro-
gression even in the absence of antimitotic drugs, causing
inhibition of mitosis (Cimini et al., 2003). In addition, a
histone deacetylase inhibitor is shown to prolong prophase,
causing chromosomal decondensation (Mikhailov et al.,
2004). Furthermore, TSA is shown to have a long-term neg-
ative effects on mitosis, causing defects in chromosomal
segregation due to an alteration of pericentric heterochro-
matin (Taddei et al., 2001).
Nocodazole treatment triggers a dramatic movement of
Brd4 from and to mitotic chromosomes. The redistribution
of Brd4 was dependent on properly maintained histone
acetylation, which was deficient in Brd4/ cells. Our re-
sults indicate that the Brd4 dynamics is a mechanism ensur-
ing the recovery from drug-induced mitotic arrest. The Brd4
dynamics described in this work may serve as a new para-
digm to study the contribution of chromatin to mitotic stress
responses.
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